• 30 Mar 2026
• Admin
• News Article

Novartis to Acquire Excellergy in $2 Billion Deal to Expand Allergy Pipeline

Novartis has announced plans to acquire Excellergy, Inc., a privately held biotech focused on next-generation therapies for IgE-driven allergic diseases.

The deal, valued at up to $2 billion in upfront and milestone payments—signals a strategic push by Novartis to strengthen its position in immunology and allergy treatment.

What Novartis Is Getting: Exl-111

At the center of the acquisition is Exl-111, a next-generation anti-IgE monoclonal antibody currently in Phase I development.

Key Differentiators

• High-affinity IgE binding
• Extended half-life → longer duration in the body
• Designed for:
  • Faster onset of action
  • Deeper suppression of IgE signalling
  • Improved symptom control

This positions Exl-111 as a potential upgrade over existing anti-IgE therapies.

Why IgE Matters in Allergic Diseases?

Immunoglobulin E (IgE) is a core driver of many allergic conditions, including:

• Food allergies
• Allergic asthma
• Chronic spontaneous urticaria
• Chronic inducible urticaria

The Limitation of Current Therapies

Traditional anti-IgE therapies:

• Neutralize circulating IgE
• But have limited impact on receptor-bound IgE

A New Mechanism: Going Beyond Conventional Anti-IgE

Exl-111 is designed to work differently.

Novel Mechanism of Action

• Dissociates receptor-bound IgE
• Promotes faster downregulation of:
  • Fc epsilon RI alpha (FcεRIα) receptors
• Leads to:
  • Faster symptom relief
  • Stronger disease control
  • Potential for less frequent dosing

Early Evidence

• Preclinical studies show enhanced IgE suppression
• Phase I data indicates:
  • Sustained drug exposure
  • Support for extended half-life design

If validated in later trials, this could expand use across multiple allergic diseases, including pediatric populations.

Strategic Fit for Novartis

This acquisition aligns with Novartis’ long-term focus on immunology and inflammation.

Why It Makes Sense

• Builds on existing IgE expertise
• Strengthens allergy portfolio depth
• Adds a next-gen biologic with differentiation potential

The company is aiming to:

• Move beyond incremental improvements
• Deliver meaningful clinical advantages over existing treatments

Deal Structure and Timeline

• Total value: Up to $2 billion
• Includes:
  • Upfront payment
  • Milestone-based payouts

Expected Timeline

• Deal closure: H2 2026
• Subject to:
  • Regulatory approvals
  • Standard closing conditions

Bigger Picture: The Race for Better Allergy Treatments

The allergy space is evolving rapidly:

• Rising prevalence of allergic diseases globally
• Increasing demand for targeted biologics
• Shift toward disease-modifying therapies

Exl-111 could position Novartis to compete more aggressively in this high-growth segment.

Final Take

This isn’t just another biotech acquisition. It’s a platform bet on next-generation IgE biology. If Exl-111 delivers on its promise, Novartis could:

• Redefine anti-IgE therapy standards
• Expand into broader patient populations
• Capture a larger share of the allergy biologics market

The risk? It’s still early-stage. The opportunity? A potentially best-in-class therapy in a massive and growing market.